ALS is often called the "bankruptcy disease" due to the high cost of treatments and care. But the emotional costs can take a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Short-term business financing can help you weather a cash crunch or take advantage of new opportunities, but these loans can come with high costs Written By Written by Staff Senior Editor, Buy Side ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Both funds charge the same very low expense ratio and offer identical 3.9% yields as of mid-April 2026. BSV is larger, holds fewer bonds, and has outperformed VGSH over the past year, but with a ...

Biogen (BIIB) stock received an upgrade from Wells Fargo to Overweight with a $250 price target from $200, driven by confidence in late-stage immunology and kidney pipeline programs as medium-term ...

The company continues to pivot away from its traditional strength in multiple sclerosis treatments. Its recent acquisition of Apellis Pharmaceuticals should wrap up soon, and it'll have quite an ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Myles is a former senior insurance editor for Investopedia. He oversaw the strategy ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma. The ...

Biogen BIIB0.26%increase; green up pointing triangle first-quarter profit and revenue rose, buoyed by rising sales from its growth products, led by its drug to treat early Alzheimer’s. Shares of the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Drugmakers have used the Trump ...

April 20 (Reuters) - Biogen (BIIB.O), opens new tab said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from ...